

OTHER INFORMATION
TO THE REPORT
FINANCING
GENOMTEC S.A.
FOR THE FIRST QUARTER OF 2024

Wrocław, 29 May 2024



1 Information about the report and a glossary of terms and abbreviations used in it

Genomtec Joint Stock Company based in Wrocław, address: ul. Bierutowska 57-59, 51-317 Wrocław, registered in the Register of Entrepreneurs of the National Court Register under the number 0000662554 - District Court for Wrocław Fabryczna in Wrocław VI Economic Division of the National Court Register ("**GENOMTEC**", "**GENOMTEC S.A.**", "**Company**", "**Issuer**"), NIP number: 8992809452, REGON: 365935587.

As at 31 March 2024 (the "**Balance Sheet Date**") GENOMTEC S.A.'s share capital amounted to PLN 1,225,788.60 and consisted of 12,257,886 shares with a nominal value of PLN 0.10 each ("**Shares**").

This document ("**Report**") contains the Notes of the Management Board of GENOMTEC S.A. to the quarterly condensed financial statements of GENOMTEC S.A. for Q1 2024.

The quarterly condensed financial statements in the Report are understood to mean the financial statements of Genomtec S.A. for the period 1 January - 31 March 2024 (the "**Reporting Period**") prepared in accordance with International Financial Reporting Standards as endorsed for use in the EU.

The source of the data in the Report, unless otherwise indicated, is GENOMTEC S.A.. The date of publication of the Report (the "**Report Date**") is 29 May 2024

"**WSE**" means the Warsaw Stock Exchange.

"**CCC**" means the Act of 15 September 2000. Commercial Companies Code.

"**Ordinance on current and periodic reports**" means the Ordinance of the Minister of Finance of 29 March 2018 on current and periodic information provided by issuers of securities and the conditions for recognising as equivalent the information required by the laws of a non-member state.

"Articles of Association" means the Articles of Association of GENOMTEC S.A. publicly available at <https://genomtec.com>.

"**Public Offering Act**" means the Act of 29 July 2005 on Public Offering and the Conditions for Introducing Financial Instruments to the Organised Trading System and on Public Companies.

"**Accounting Act**" means the Act of 29 September 1994 on accounting.

Unless otherwise stated, financial figures are presented in thousands.

TABLE OF CONTENTS

1	INFORMATION ABOUT THE REPORT AND A GLOSSARY OF TERMS AND ABBREVIATIONS USED IN IT	2
2	LETTER FROM THE MANAGEMENT BOARD	4
3	SELECTED FINANCIAL DATA.....	5
4	OTHER INFORMATION TO THE QUARTERLY FINANCIAL STATEMENTS.....	5
5	SHAREHOLDERS AND SHARES OF THE COMPANY	16



2 Letter from the Management Board

Dear Shareholders and Investors

We bring you the report of the Company Genomtec S.A., which summarises the events of Q1 2024. The beginning of this year was very intensive for us, both in terms of the development of our technology for the application of our proprietary SNAAT® method based on the amplification of genetic material in the LAMP technique in the field of infectious disease diagnostics, and in our efforts to secure funding for the development of our prospective oncology project 'OncoSNAAT'. A major development was also the introduction of new experts with international experience to the Company's Supervisory Board, who actively support Genomtec in achieving the Company's strategic goals.

Our most advanced project related to infectious disease diagnostics, the Genomtec ID platform, is progressing according to plan. In the first quarter, we focused on optimising the cost of future production and operation of the platform, the ability to scale up production - both reaction card and reagents, and the analyser. We also continued with the Genomtec ID clinical trial for respiratory infectious diseases, analysing patient samples that came into our laboratory each week. Upon completion of the trial, we will apply for Genomtec ID certification in accordance with IVDR requirements. It is worth noting that the deadline for certification has been extended to 2029.

A major challenge was to secure the capital for the own contribution to the grant we received for our oncology programme "OncoSNAAT" under the European Funds for Modern Economy programme organised by the Polish Agency for Enterprise Development (PARP), the amount of the grant awarded is PLN 21.6 million and the total project budget will be approximately PLN 36.7 million. We successfully led a capital increase in March this year, in which Genomtec concluded an investment agreement with ten significant shareholders of the company, including the company's founders and a foreign investor. As a result, more than PLN 10 million was raised, which will almost entirely be used to invest in the further development of the oncology project "OncoSNAAT" - key to the company's value growth and potential M&A transaction.

The development of our technology and growing international recognition has resulted in a significant strengthening of the company's Supervisory Board, through the appointment of experts with extensive industry and scientific experience. In March and April this year, our Supervisory Board was joined by: Gualtiero Garlasco, Beata Turlejska and Dr Trevor Hawkins. Gualtiero Garlasco is a MedTech industry veteran with extensive business development experience and Dr Trevor Hawkins is a seasoned research and commercial operations leader in global healthcare companies. Ms Beata Turlejska, meanwhile, brings to the Board experience in building companies and developing businesses across a range of industries.

In April, we were present at the ECCMID 2024 conference in Barcelona, where, with the support of our partner Clairfield Partners, we were in active discussions with potential companies interested in acquiring our technology. We will also be at the next industry conference in June - BIO 2024 in San Diego, where we will have the opportunity to meet and talk to potential partners from the world's leading diagnostics barage, with whom we will discuss opportunities for collaboration, including in the context of M&A transactions.

At this point, we would like to thank our Shareholders and investors for the trust they have placed in us, especially with the support they have given us in obtaining financing. We thank our employees for their contribution to the development of Genomtec's business. We would like to invite you all to read the quarterly report, and if you have any questions, we are at your disposal through our Investor Relations Team: investors@genomtec.com

Yours sincerely,

Management Board of Genomtec S.A.



3 Selected financial data

in thousands	01.01.2024 - 31.03.2024 [PLN].	01.01.2023 - 31.03.2023 [PLN].	01.01.2024 - 31.03.2024 [EUR].	01.01.2023 - 31.03.2023 [EUR].
Sales revenue	0	90	0	19
Cost of sales	0	0	0	0
Grant income	266	50	62	11
Research and development costs	457	67	106	14
General administration and selling expenses	2 500	2 108	579	448
Operating result	-2 613	-2 033	-605	-433
Net result	-2 658	-2 079	-615	-442
Equity	5 644	8 302	1 312	1 909
Cash and cash equivalents	6 785	4 169	1 578	959
Total assets	17 208	15 972	4 001	3 673
Long-term liabilities	4 193	4 526	975	1 041
Current liabilities	7 371	3 144	1 714	723

In order to convert the items shown in the "Selected financial data" table into euros, the items in the statement of financial position were converted using the average exchange rate of the National Bank of Poland (NBP) in force on the day ending the reporting period.

The items of the cash flow statement and income statement have been translated according to the arithmetic average of the average exchange rates announced by the National Bank of Poland on the last day of each completed month of the period, at the euro exchange rate of 4.3211 for the data for the period ending 31.03.2024, and at the euro exchange rate of 4.7005 for the data for the period ending 31.03.2023.

Asset and liability items and cash at the end of the period have been translated according to the average exchange rate in force at the balance sheet date at a euro exchange rate of 4.3009 for the data for the first quarter ending 31.03.2024 and at a euro exchange rate of 4.3480 at 31.03.2023.

4 Other information to the quarterly financial statements

4.1 Basic data of the Company

Name (company):	GENOMTEC S.A.
Headquarters	Wrocław
Address:	57-59 Bierutowska Street, 51-317 Wrocław
KRS:	0000662554
NIP	8992809452
REGON:	365935587
Register Court	District Court for Wrocław-Fabryczna in Wrocław, VI Economic Division KRS
Share capital	PLN 1 332 457.00



Telephone number +48 793 440 931

Web address <http://www.genomtec.com/>

Email: office@genomtec.com

The company has the status of a public company, whose shares have been listed on the main market of the Warsaw Stock Exchange since 16.02.2023.

In terms of financial reporting, the Company applies IAS/IFRS principles.

The Company's financial year runs from 1 January to 31 December.

4.2 History and objects of the Company

Genomtec S.A., headquartered in Wrocław, Poland (Company, Issuer, Genomtec), was founded in 2016 by a group of scientists and engineers with experience and expertise in the fields of molecular biology and microsystems and photonics.

The Company's core business is research and development in the field of biotechnology.

The company's flagship project is Genomtec ID, a diagnostic system with the potential to become the new standard in diagnostics, thanks to the mobility, speed and efficiency of the device, which can detect pathogens such as viruses, bacteria or fungi, as well as genetic mutations through the analysis of biological material: swabs, urine, saliva.

The Genomtec ID is a handy diagnostic system with a cuboid shape and dimensions of approximately 10cm x 10cm x 15cm, which stands out for its mobility and speed of testing while maintaining the highest standards for sensitivity and specificity. The Genomtec ID will be able to test up to five pathogens simultaneously on a single reaction card, which, in the opinion of the Board, represents optimum information value for the test analyser.

In 2023, the Company, started work on the development of a new diagnostic platform operating on the basis of isothermal amplification techniques of nucleic acids. The project aims to develop technology and an automated system for mutation detection in the area of clinical oncology based on a lab-on-chip solution and isothermal nucleic acid amplification techniques for, among other things, the selection of targeted therapies in the area of oncology.

As at the date of publication of this report, the Company does not form a group and there are no subsidiaries of the Company. The Company has no branches.

During the reporting period, there were no changes to the Company's basic business management principles.

On 16 February 2023. The company made its debut on the WSE Main Market.

Object of activity

Genomtec S.A.'s activities consist of research and development in the area of the application of isothermal methods in molecular diagnostics.

Another area of the Company's activity is the development and commercialisation of genetic tests with applications in, among others, the detection of infectious diseases with a viral basis, including COVID-19, caused by the SARS-CoV-2 virus. However, the activities in the area of testing are treated by the



Board as side activities, and the Company's most important projects are Genomtec ID and the oncology project "OncoSNAAT".



The experience gained from scientific and business projects has enabled the development of a technology that is free of the disadvantages of the currently dominant approach to genetic diagnostics, including, in particular, *Point of Care Testing* (POCT) - i.e. instrument size, power consumption, time to result, cost of production of the analyser and reaction cards.

With this in mind, the Issuer decided to develop its equipment based on the rapidly developing isothermal method of amplification of genetic material using the LAMP technique. The Company uses a proprietary automated version of this method called SNAAT® (*Streamlined Nucleic Acid Amplification Technology*). The annual market growth rate for isothermal nucleic acid amplification techniques is estimated to be significantly higher than the current market standard, the *Polymerase Chain Reaction* (PCR).

4.2.1 Management

The Company's governing body is the Board of Directors.

The Management Board consists of up to 5 (five) Members, appointed by the Supervisory Board, including the President and the Vice-President or Vice-Presidents if the Management Board is composed of several Members.

The joint term of office of the Board Members is 3 years. Each Member of the Management Board may be elected for a further term of office. A Member of the Management Board may be dismissed or suspended for important reasons by the Supervisory Board.

The terms of office of the members of the Management Board shall expire at the latest on the date of the General Meeting approving the financial statements for the last full financial year in which they served as members of the Management Board.

The composition of the Issuer's Board of Directors as at the Balance Sheet Date and the Report Date was as follows:

- Miron Tokarski President of the Management Board
- Michał Wachowski Member of the Management Board
- Charudutt Shah Member of the Management Board




dr Miron Tokarski
Chief Executive Officer (CEO)

Miron jest współzałożycielem firmy Genomtec S.A i jej prezesem. Jest także diagnostą laboratoryjnym. Absolwent Wydziału Farmaceutycznego z Oddziałem Analityki Medycznej Uniwersytetu Medycznego we Wrocławiu. Tytuł doktora nauk medycznych w dziedzinie biologii molekularnej uzyskał w grudniu 2021 od Uniwersytetu Medycznego we Wrocławiu.

Autor publikacji oraz współautor patentów Genomtec. Ambitny, młody naukowiec. Jego praca magisterska została nagrodzona przez Fundację Hasco-Lek. Kierownik projektu badawczego Narodowego Centrum Nauki.

W Genomtec Miron uczestniczy aktywnie w pracach B+R w zakresie biologii molekularnej w obszarze chorób zakaźnych.


Michał Wachowski
Członek Zarządu, Chief Financial Officer (CFO)

Michał ma ponad 14 letnie doświadczenie w obszarze finansowania przedsiębiorstw, zarządzania inwestycjami oraz doradztwa biznesowego. Przed dołączeniem do zespołu pełnił rolę dyrektora inwestycyjnego w aktywnie inwestującym funduszu typu Venture Capital. Wcześniej był członkiem Zarządu średniej wielkości spółki produkcyjnej z sektora energetycznego oraz wiceprezesem ds. finansowych w start-upie z branży chemicznej. Doradzał w szeregu transakcji z zakresu inwestycji, fuzji oraz przejęć oraz w procesach restrukturyzacyjnych. Wcześniej pełnił funkcje operacyjne w ARP, TFS, Deloitte, Polimex-Mostostal oraz Central Europe Trust. Absolwent studiów magisterskich Szkoły Głównej Handlowej w Warszawie na kierunku Finanse i Bankowość oraz studiów podyplomowych Transfer Technologii Informatycznych do Przedsiębiorstw.

W Genomtec odpowiedzialny za finanse Spółki.


Charudutt Shah
Członek Zarządu

Charudutt Shah posiada kilkunastoletnie doświadczenie kierownicze w obszarze komercjalizacji produktów, rozwoju marek i partnerstwa z międzynarodowymi podmiotami. Jest menadżerem wyższego szczebla z wieloletnim, międzynarodowym doświadczeniem m.in. w obszarze rozwoju biznesu, zarządzaniu marketingiem i sprzedażą oraz planowaniu strategicznym w sektorze genetycznej diagnostyki klinicznej. Swoją pracę w Genomtec rozpocznie od 1 sierpnia 2021. W swojej pracy główny nacisk kładzie na rozwój strategii wejścia na rynek, zwiększanie świadomości klinicystów, dostęp do rynku oraz wprowadzanie innowacyjnych rozwiązań w zakresie testów do różnych ekosystemów opieki zdrowotnej w celu poprawy opieki nad pacjentami.

Charudutt jest absolwentem Uniwersytetu w Toronto i posiada zarówno tytuł licencjata w dziedzinie nauk stosowanych i inżynierii, jak i magistra biotechnologii i zarządzania. Posiada również certyfikat studiów z zarządzania sojuszami strategicznymi firm wydany przez Canadian Healthcare Licensing Association.

4.2.2 Supervisory Board

The Supervisory Board exercises constant supervision over the Company's activities in all areas of its business. In accordance with the Company's Articles of Association, the Supervisory Board consists of 5 (five) to 7 (seven) members, including the Chairman. Members of the Supervisory Board are appointed and dismissed by the General Meeting for a joint term of 3 years. Any Member of the Supervisory Board may be re-elected to this function. Any Member of the Supervisory Board may be dismissed at any time. If the General Meeting has not elected the Chairman of the Board, he/she shall be elected at the first meeting in a given term of office by the Supervisory Board from among its members. The term of office of a member of the Supervisory Board shall expire, at the latest, on the date of the General Meeting which approves the financial statements for the last full financial year in which the member served on the Supervisory Board.

The composition of the Issuer's Supervisory Board at the end of 2023 was as follows:

- Karol Hop Chairman of the Supervisory Board
- Michał Jank Member of the Supervisory Board
- Andrzej Taudul Member of the Supervisory Board
- Paweł Duszek Member of the Supervisory Board
- Jarosław Oleszczuk Member of the Supervisory Board

On 12 March 2024, changes took place in the composition of the Company's Supervisory Board, with Mr Jarosław Oleszczuk resigning as a Member of the Issuer's Supervisory Board with effect from the



time of submission, and Mr Karol Hop submitting a statement of resignation from the Company's Supervisory Board at the opening of the Extraordinary General Meeting of the Company convened for 12 March 2024. On the same day, the Extraordinary General Meeting of the Company decided to appoint new members of the Supervisory Board of the Issuer in the persons of Ms Beata Turlejska and Mr Gualtiero Garlasco

On 22 April 2024, the Company received the resignation of Mr Michael Jank from the Supervisory Board of the Company with effect from the opening of the Extraordinary General Meeting of the Company convened for 22 April 2024, and on the same date the Extraordinary General Meeting of the Company appointed Mr Trevor Hawkins to the Supervisory Board of the Company.

The composition of the Issuer's Supervisory Board as at the Balance Sheet Date and the Report Date was as follows:

- Beata Turlejska Chairperson of the Supervisory Board
- Andrzej Taudul Member of the Supervisory Board
- Trevor Hawkins Member of the Supervisory Board
- Paweł Duszek Member of the Supervisory Board
- Gualtiero Garlasco Member of the Supervisory Board

The Supervisory Board may appoint committees or commissions, both permanent and ad hoc, to deal with specific matters, as consultative and advisory bodies consisting of individual Supervisory Board Members, advisers and experts.

4.2.3 Audit Committee

The Audit Committee was appointed from among the members of the Supervisory Board on the basis of Resolution No. 01/10/2021 of the Supervisory Board dated 22.10.2021.

The Audit Committee operates on the basis of the Rules of Procedure of the Audit Committee adopted by the Company's Supervisory Board, which sets out, among other things, the detailed scope of the Committee's tasks and powers.

As at the Report Date, the composition of the Audit Committee was as follows:

- Paweł Duszek - Chairman of the Audit Committee
- Trevor Hawkins - Member of the Audit Committee
- Beata Turlejska - Member of the Audit Committee

4.3 Strategy and objectives

The Company focuses on research and development activities. The Company's strategic objective is to develop key technological and scientific competencies in order to maximise the effect of ongoing tasks related to current projects. The Company currently does not have the capacity and production resources for mass production of devices or reaction cards, and the development strategy does not assume that such production capacity would be implemented by the Company on its own. The Company's development strategy is to develop innovative technologies within its in-house scientific team, secure intellectual value through patents and patent applications and commercialise projects in collaboration with external partners.



The Company's strategic objective is therefore to achieve the ability to commercialise and market the results of the work carried out by the Company's specialists. This currently primarily concerns the flagship project, the Genomtec ID diagnostic system, and the oncology project.

For the Company, the strategic projects are Genomtec ID and the development of the oncology project, and the Company is currently investing the most time and resources in the development of these projects. The strategy for the development of these products was to certify them before an authorisation body in Europe and to achieve external small-scale production capacity, which took place in the second half of 2022 for Genomtec ID. The market sale of the results of the Company's work can, in principle, take place in one of two basic formulas: strategic partnerships and licensing, or the sale of the technology, which are options that the Company is currently analysing and for which it is seeking a business partner or investor. Work in this area was stepped up at the end of 2022 with the start of cooperation with Clairfield Partners LLC. The object of the concluded agreement is to advise on the process of establishing strategic partnerships, selling licenses and/or selling all or part of its intellectual property and related technology. According to the concluded agreement, Clairfield Partners LLC is responsible for, among other things, the identification and selection of potential buyers and partners. These activities include, among other things, drafting the necessary materials and establishing contacts with, among others, global companies in the in-vitro diagnostic medical device sector.

Since the start of R&D, the company has been taking measures that make successful market commercialisation likely, such as:

- cooperation with international partners such as CDMOs in the area of reaction cards and the analyser, which lends credibility to the production capacity in the eyes of international players;
- the development of a team of specialists with international experience in the commercialisation of medical devices;
- taking care to protect intellectual property through granted patents and patent applications, thus building the value of the technology.

In parallel, utilising the overseas contacts of those working or collaborating with the Company, including the UK team and the industry experience of Mr Charudutt Shah, Member of the Board, the Company is in discussions with potential business partners presenting its technology and commercial opportunities. The company also participates in trade fairs and industry conferences.

At the date of publication of this Report, the Board has not decided on a single route to market the Company's output. The main criterion that the Management Board will take into account when choosing the appropriate route is the maximisation of the Company's shareholder value and the efficiency of the Company's development.

As of the date of publication of this report, the review of strategic options, which the Company reported on, inter alia, in current report No. 27/2022 and 4/2023, remains ongoing.



4.4 Company development projects

4.4.1 Genomtec ID



Genomtec ID is the Company's flagship technology solution that offers rapid genetic diagnostics using SNAAT® technology. The Genomtec ID system allows the diagnostic process to be carried out at the point of patient care (e.g. primary care clinics, pharmacies, doctors' surgeries, hospital emergency departments (EDs)) without the need for its complex and time-consuming handling in the laboratory by qualified personnel. Currently, the Genomtec ID platform is in the industrialisation phase in collaboration with an external partner (*Contract Development and Manufacturing Organisation - CDMO*).

In Q2 2022, the Issuer reached a significant milestone of obtaining the CE-IVD mark for its flagship solution, the Genomtec®ID Respiratory Panel 5-Plex (RP5-PLEX) diagnostic panel for the detection of pathogens that cause respiratory diseases, required for all in-vitro diagnostic (IVD) devices to be marketed in the countries of the European Economic Area (EEA) and Iceland, Norway and Liechtenstein. GENOMTEC has filed an application for a new in-vitro diagnostic medical device with the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products and, following the expiry of the statutory deadline for the application, has been granted the right to market the Genomtec ID Respiratory Panel 5 - Plex product in the European Union (*ESPI current report number 12/2022 of 8 June 2022*).

4.4.2 Oncology project

The oncology project 'oncoSNAAT' is a method developed by Genomtec that uses SNAAT® technology for cancer diagnosis for use in distributed diagnostics. The project consists of the development of technology and an automated system for the detection of genetic variants in the field of clinical oncology based on a lab-on-chip solution and isothermal nucleic acid amplification techniques. The R&D work will include lab-on-chip technology for the detection of genetic variants in oncology diagnostics using microfluidic cards to enable the diagnosis and application of molecularly targeted therapies. In the course of further work, the technology will be developed using a dedicated analyser and a clinical trial will be conducted.

Furthermore, in addition to the areas of upper respiratory disease diagnostics or oncology, which are among the most attractive segments of the diagnostics market, the technology under development can be used in: the area of drug dosage, epidemiology, veterinary diagnostics or food safety, among others. The project started in January 2024 and will last until 2027.

4.5 Intellectual property

Patent protection of the technology held or the processes comprising the technology is a key area for building and protecting the intellectual value developed in the Company.

As at the date of this report, the Company holds patents in Europe, the USA, Canada, Brazil and Japan. In addition, the Company has more than 30 patent applications in global markets.

List of the Issuer's patents:

Lp.	Patent number	Country of application	Title	Validity
1	Pat. 235210	Poland	Method of detecting genetic material in a biological sample and a device for its implementation	21.12.2036
2	US 10781479	USA	A method of detecting genetic material in a biological sample and a device for its implementation	21.12.2037
3.	237232	Poland	Borrelia burgdorferi nucleotide sequence duplication primer set, Borrelia burgdorferi detection method, Lyme disease diagnostic method and Lyme disease diagnostic kit	20.10.2037
4.	6961700	Japan	Method for detection of genetic material in a biological specimen, the device for the execution of this method	20.12.2037
5	Pat.239727	Poland	Non-contact temperature monitoring kit, method of generating electromagnetic radiation wave fronts and use of the kit to generate temperature field profiles	03.01.2038
6	Pat.240016	Poland	Human papillomavirus type 16 HPV16 Human papillomavirus type 16 detection primer set, how to detect HPV16 infection, use of HPV infection detection primer set	09.09.2039



Lp.	Patent number	Country of application	Title	Validity
7	338891	Albania, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Montenegro, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Monaco, the Netherlands, Norway, Portugal, Romania, San Marino, Serbia, Slovakia, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States.	A method of detecting genetic material in a biological sample and a device for its implementation	20.12.2037
8	63179	Serbia	Method of detecting genetic material in a biological sample and a device for its implementation.	20.12.2037
9	BR 112019012501-9	Brazil	Method of detecting genetic material in a biological sample and a device for its implementation (UM MÉTODO PARA DETECTAR MATERIAL GENÉTICO EM UMA AMOSTRA BIOLÓGICA E	20.12.2037



Lp.	Patent number	Country of application	Title	Validity
			UM DISPOSITIVO PARA SUA IMPLEMENTAÇÃO)	
10	11608521	USA	Method of detecting genetic material in a biological sample and a device for its implementation (continuation)	23.10.2037
11	PAT.88667-1	Canada	A method of detecting genetic material in a biological sample and a device for its implementation	20.12.2037
12		Poland	Mycoplasma pneumoniae dnaE gene nucleotide sequence duplication primer set, Mycoplasma pneumoniae detection method, Mycoplasma pneumoniae infection detection method and Mycoplasma pneumoniae infection detection kit	

4.6 Sources of funding

In order to raise additional funding for the development of the Company's activities, in particular the oncology project 'OncoSNAAT', on 22 April 2024, the Extraordinary General Meeting of the Company adopted a resolution to issue up to 1,066,684 new series O ordinary bearer shares with a nominal value of PLN 0.10. The issue price of series O shares was PLN 10.00. As part of the issue of O series shares, the Company raised PLN 10,666,840. The capital increase by O series shares took place on 16 May 2024.

4.7 Description of the Issuer's significant achievements or failures during the Reporting Period, including a list of the most significant events

4.7.1 Recognition by NCRD of the project implemented by the Company as completed

On 29 January 2024, the Company received information from the National Centre for Research and Development that the NCBR recognised the project implemented by the Company entitled "Development of technology and mobile diagnostic equipment based on a lab-on-chip solution for the detection of infectious diseases." as completed in terms of content and finance. The Project was subsidised by NCBR, and according to the subsidy agreement with NCBR, the Company is obliged to ensure the sustainability of the Project for a period of 3 years. The total cost of the Project was approximately PLN 12.2 million, the NCRD grant awarded was approximately PLN 8.9 million. (ESPI current report no. 2/2024).



4.7.2 Grant of patent in Canada

On 12 February 2024, the Company became aware of a positive decision by the Canadian Patent Office granting the Company patent protection for *its invention entitled "A method of detecting genetic material in a biological sample and a device for its implementation"*. (ESPI current report no. 3/2024).

4.7.3 Receipt of a decision from the Polish Patent Office granting patent protection

On 28 February 2024, the Company became aware of a positive decision by the Polish Patent Office granting the Company patent protection for the invention entitled *"A set of primers for duplicating the nucleotide sequence of the dnaE gene of Mycoplasma pneumoniae, a method for detecting Mycoplasma pneumoniae bacteria, a method for detecting Mycoplasma pneumoniae infection and a kit for detecting Mycoplasma pneumoniae infection"*. (ESPI Current Report No. 5/2024).

Changes to the Supervisory Board of Genomtec S.A.

On 12 March 2024, changes to the composition of the Company's Supervisory Board took place, with Mr Jarosław Oleszczuk resigning as a Member of the Issuer's Supervisory Board effective as of the time of submission, and Mr Karol Hop submitting a statement of resignation from the Company's Supervisory Board as of the opening of the Extraordinary General Meeting of the Company convened for 12 March 2024. On the same day, the Extraordinary General Meeting of the Company decided to appoint new members to the Issuer's Supervisory Board in the persons of Ms Beata Turlejska and Mr Gualtiero Garlasco. (ESPI current report no. 6/2024).

Conclusion of an investment agreement to increase the Company's share capital

On 26 March 2024, the Company entered into an investment agreement with ten shareholders of the Company, including 5HT Family Foundation, the President of the Company's Management Board, Miron Tokarski, and the Company's founders, pursuant to which the aforementioned shareholders undertook to provide financing to the Company by taking up a total of 1,066,684 new ordinary bearer shares issued by the Company for a unit issue price of PLN 10.00. On 22 April 2024, the Extraordinary General Meeting of the Company adopted a resolution to increase the Company's share capital (ESPI Current Report No. 11/2024 and 13/2024)

4.8 Events after the Balance Sheet Date

Resolution on the issue of shares and changes in the Supervisory Board

On 22 April 2024, an Extraordinary General Meeting of the Company took place, which adopted a resolution to increase the Company's share capital through the issue of up 1,066,684 new series O ordinary bearer shares the exclusion of all pre-emptive rights of existing shareholders, to amend the Company's articles of association and to apply for the admission and introduction of the series O shares to trading on the regulated market (ESPI current report No. 13/2024).

In addition, on the same day, the Company received the resignation of Mr Michael Jank from the position of Member of the Supervisory Board of the Company with effect from the opening of the Extraordinary General Meeting, and during the Extraordinary General Meeting, Mr Trevor Hawkins was



appointed to the position of Member of the Supervisory Board of the Company as of the same date (ESPI current report No. 14/2024)

Registration of share capital increase

On 16 May 2024, amendments to the Company's Articles of Association resulting from the aforementioned resolution of the Extraordinary General Meeting of the Company of 22 April 2024 on increasing the Company's share capital through the issue of new O series ordinary bearer shares were registered by the District Court for Wrocław Fabryczna in Wrocław, 6th Commercial Division of the National Court Register.

5 Shareholders and Company shares

The Company's registered share capital as at the Report Date is PLN 1,332,457, divided into 13,324,570 ordinary bearer shares with a nominal value of 0.10 (ten cents) per share.

The Company's share capital is divided into:

- (a) 1,000,000 series A ordinary bearer shares,
- (b) 142,860 Series B ordinary bearer shares,
- (c) 4,000,000 Series C ordinary bearer shares,
- (d) 583,670 series D ordinary bearer shares,
- (e) 85,900 series E ordinary bearer shares,
- (f) 76,000 series F ordinary bearer shares,
- (g) 710,110 G-series ordinary bearer shares,
- (h) 830,000 series H ordinary bearer shares,
- (i) 730,000 J series ordinary bearer shares,
- (j) 1,205,639 series K ordinary bearer shares,
- (k) 794,361 series L ordinary bearer shares,
- (l) 1,237,000 series M ordinary bearer shares,
- (m) 400,000 series N ordinary bearer shares,
- n) 462,346 Series I ordinary bearer shares, and
- (o) 1,066,684 Series O ordinary bearer shares.


The company does not hold any treasury shares.

The shareholding structure of the Issuer at the date of this report is as follows:

Shareholder	Number of shares	Number of votes	Share in the share capital	Share in the number of votes at the AGM
Leonarto Funds SCA	1 650 620	1 650 620	12,39%	12,39%
Miron Tokarski	1 365 618	1 365 618	10,25%	10,25%
Others	10 318 832	10 318 832	77,44%	77,44%
TOTAL	13 324 570	13 324 570	100,00%	100,00%



Shareholding structure at the date of publication of this Report.



From the date of publication of the previous interim report, i.e. the annual report for 2023, i.e. from 25 April 2024, there was a change in the ownership structure of significant blocks of the Issuer's shares resulting from the registration in the KRS of 1,066,684 series O ordinary bearer shares and, in addition, the President of the Company's Management Board, Miron Tokarski, acquired 10,500 series O shares, of which the Company informed in current report ESPI No. 17/2024.

The shareholding structure of the Issuer at the date of publication of the previous interim report was as follows:

Shareholder	Number of shares	Number of votes	Share in the share capital	Share in the number of votes at the AGM
Leonarto Funds SCA (<i>société en commandite par actions</i>)*	1 650 620	1 650 620	13,47%	13,47%
Miron Tokarski	1 355 118	1 355 118	11,06%	11,06%
Others	9 252 148	9 252 148	75,48%	75,48%
TOTAL	12 257 886	12 257 886	100,00%	100,00%

*according to the notification published by the Company in the current report ESPI No. 9/2024 Leonarto VC Pankiewicz Spółka jawna obtained the status of a dominant entity with respect to Leonarto Funds SCA. Leonarto VC Pankiewicz Spółka jawna holds directly 1,000 shares in the Company representing 0.008% of the share capital of the Company and entitling to 1,000 votes, representing 0.008% of the total number of votes and holds indirectly through the company Leonarto Funds SCA seated in Luxembourg, registered in the Luxembourg Trade Register under number B234200, which is a subsidiary of the Shareholder (through Leonarto VC Pankiewicz Spółka jawna Spółka komandytowa, which is a subsidiary of the Shareholder and the parent entity of Leonarto Funds SCA), 1 650 620 shares in the Company, representing 13.47% of the share capital of the Company and entitling to 1 650 620 votes, representing 13.47% of the total number of votes.



As at the Reporting Date, the following members of the Company's management and supervisory bodies hold Shares in the Company:

Shareholder	Number of shares/votes held	Nominal value of shares (PLN)	Share in the share capital	Share in the number of votes at the AGM
Miron Tokarski - President of the Management Board	1 365 618	136 561,80	10,25%	10,25%
Michał Wachowski - Member of the Management Board	45 006	4 500,60	0,37%	0,37%
Charudutt Shah - Member of the Management Board	94 123	9 412,30	0,77%	0,77%
Beata Turlejska - Chairman of the Supervisory Board	833	83,3	0,01%	0,01%
Trevor Hawkins - Member of the Supervisory Board	0	0	0,00%	0,00%
Paweł Duszek - Member of the Supervisory Board	0	0	0,00%	0,00%
Andrzej Taudul - Member of the Supervisory Board	3 441	344	0,03%	0,03%
Gualtiero Garlasco - Member of the Supervisory Board	0	0	0,00%	0,00%

At the date of publication of the report, none of the Company's management and supervisory bodies are entitled to shares in the Company (other than under the incentive scheme), nor do they hold shares in related parties.

Since the date of the previous interim report, i.e. the annual report for 2023 published on 25 April 2024, apart from changes resulting from the registration in the KRS of 1,066,684 series O ordinary bearer shares and the acquisition of series O shares by the President of the Company's Management Board, there have been no other changes in the ownership of the Issuer's shares by the Issuer's managing and supervising persons.

5.1 Description of factors and events, in particular of an unusual nature, having a significant impact on the Company's financial performance

Apart from the information provided in this report, the Company does not identify any factors or unusual events affecting the results of operations for the financial year.



5.2 Indication of factors which, in the Issuer's opinion, will affect its results in the perspective of at least the next quarter

The Company does not generate any material revenue from the sale of its products, and the sales revenue it reports results from one-off orders for customers. The Company's products currently ready for sale are GENOMTEC's genetic tests - Genomtec® SARS-CoV-2 EvaGreen® RT-LAMP CE-IVD Duo Kit. In the Company's opinion, Genomtec's tests have a number of advantages over the currently used genetic tests using the RTPCR method, among which are the lower cost, the possibility of taking a sample from saliva (simpler, less inconvenient for the patient) and the lower level of detection. However, the company points out that in Poland, RT-LAMP genetic tests are not reimbursed by the public payer (NFZ) and are therefore subject to full payment by the patient. Until RT-LAMP tests are recognised as diagnostically equivalent to RT-PCR tests and covered by reimbursement, sales of the Company's tests must focus on cooperation with private facilities, which limits the market. The aforementioned lack of reimbursement is the main reason for not achieving significant revenues from the sale of genetic tests in Poland. In European markets, RT-LAMP tests are reimbursed in some countries such as the Netherlands, Germany, Spain, the UK, Austria and Belgium. The Company's flagship project, the Genomtec ID platform, which is in the development stage, is not currently available for sale. The Company has obtained IVDD certification and achieved external small-scale production capacity in the second half of 2022. The development of large-scale production and sales (acquisition of full commercialisation capacity), will take place in 2023 and 2024. Further funding for the development of Genomtec ID and thus the possible achievement of significant revenues from the commercialisation of this technology will be possible if the subsequent tranches of grants and subsidies received, which are crucial (in addition to contributions from investors) as external sources of funding for the Company's operations, are properly accounted for and received. On 30 November 2022, it entered into an agreement with Clairfield Partners LLC, based in New York, to advise on the process of establishing strategic partnerships, selling licences and/or selling all or part of its intellectual property and related technology. Clairfield is responsible for, among other things, identifying and selecting potential buyers and partners. These activities will include, among other things, drafting the necessary materials and establishing contacts with, among others, global companies in the in-vitro diagnostic medical device sector. In addition, Clairfield will support the Company in organising the due diligence process, shaping the negotiation strategy and coordinating the process of final discussions related to the potential transaction.

5.3 Description of changes in the organisation of the Issuer's capital group

The Issuer does not form a Capital Group.

5.4 Information on the conclusion by the Issuer of one or more transactions with related parties, if such transactions were concluded on conditions other than market conditions

The Company did not enter into transactions with related parties on other than arm's length terms during the reporting period.

5.5 Position regarding the possibility of fulfilment of the published result forecasts for a given year in the light of the results presented in this Report in relation to the forecast results

The company does not publish financial forecasts.



5.6 Indication of significant proceedings pending before a court, an authority competent for arbitration proceedings or a public administration body

During the period covered by this Report, the Company was not a party to any proceedings pending before any court, arbitration body or public administration authority concerning the Issuer's liabilities or receivables.

5.7 Information on the Issuer's granting of credit or loan sureties or guarantees

During the Reporting Period, the Issuer did not issue any sureties or guarantees

5.8 Other information which, in the issuer's opinion, is material for the assessment of its human resources, assets, financial position, financial performance and their changes, and information which is material for the assessment of the issuer's ability to fulfil its obligations

In the opinion of the Company's Board of Directors, apart from the information contained within this report, there is no other information which, in the opinion of the Company, is material for the assessment of its human resources, assets, financial position, financial result and their changes and information which is material for the assessment of the Company's ability to fulfil its obligations.

5.9 Statement of the Management Board regarding the information contained in the Report

The Management Board of GENOMTEC S.A. declares that, to the best of its knowledge, the selected financial information for Q1 2024 presented in the Report has been prepared in accordance with the regulations applicable to the Company and that the information on operations presents a true picture of GENOMTEC S.A.'s development, achievements and situation.

The report was approved for publication on 29 May 2024.



Miron Tokarski
Prezes Zarządu



Michał Wachowski
Członek Zarządu



Charudutt Shah
Członek Zarządu